• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Which SSRI Is Best for Panic Disorder?
Research Update

Which SSRI Is Best for Panic Disorder?

August 7, 2023
Rushaniya Khairova, MD, PhD.
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Rushaniya Khairova, MD, PhD. Dr. Khairova has no financial relationships with companies related to this material.

REVIEW OF: Chawla N et al, BMJ 2022;376:e066084

STUDY TYPE: Systematic review and network meta-analysis

Many medications are effective for panic disorder (PD), including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors (MAOIs). Guidelines recommend SSRIs first line, but it’s not clear how these options compare in efficacy and tolerability. This network meta-analysis aimed to address that.

The investigators searched three databases to identify randomized controlled trials that evaluated medications to treat PD (with or without agoraphobia). A total of 87 studies involving 12,800 participants and 12 drug classes met the inclusion criteria. The mean age was 35 years, the majority were women (64%), and the average duration of PD was 6.9 years. The authors used a two-stage network meta-analysis to estimate the relative efficacy of drug classes and individual SSRIs. The probability that each individual agent had the best balance of efficacy and tolerability was measured using the surface under the cumulative ranking (SUCRA). SUCRA values are presented in parentheses below, where higher values indicate a higher rank. 

The two main outcomes were remission (defined as no panic attacks for at least one week at the end of study) and dropout rates. The secondary outcomes were adverse effects and symptom scores for depression and anxiety as measured by the HAM-D, MADRS, and HAM-A rating scales. 

For remission, the most effective treatments were benzodiazepines (84.5%), TCAs (68.7%), and SSRIs (66.4%). The least effective were beta blockers (9%) and buspirone (33.2%). Dropout rates were the lowest for benzodiazepines and benzodiazepines plus TCAs, and highest for buspirone and MAOIs. However, adverse effects were lowest for buspirone and SNRIs, and highest with TCAs and benzodiazepines.

In terms of secondary outcomes, overall anxiety was most effectively decreased by SSRIs plus beta blockers (97.5%), TCAs plus benzodiazepines (70.9%), and SSRIs alone (62.9%). SNRIs and buspirone were the least effective (31.6% and 33%, respectively). For comorbid depressive symptoms, the top ranked treatments were SSRIs plus beta blockers (99.7%), benzodiazepines (69.9%), and TCAs (66.4%).

When considering the balance of efficacy and tolerability, SSRIs rose to the top, and sertraline and escitalopram ranked at the top within that class. Although fluvoxamine, paroxetine, and fluoxetine had favorable efficacy profiles, they were also associated with a higher risk of adverse effects. Citalopram had minimal efficacy and a high risk of adverse effects.

Network meta-analyses are limited by an underlying assumption that studies of varied design are comparable. In particular, this analysis was further limited by a high risk of within-study bias, inconsistency and imprecision of reported findings, and short trial durations.

CARLAT TAKE

Among pharmacotherapy options, this study supports sertraline and escitalopram as the first choice for panic disorder. Interpret with caution, as the limitations are many.

General Psychiatry Research Update
KEYWORDS anxiety disorders benzodiazepines panic disorder psychopharmacology sertraline ssris
    Rushaniya Khairova, MD, PhD.

    More from this author
    www.thecarlatreport.com
    Issue Date: August 7, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Adult Autism, TCPR, August 2023
    Stimulant Dosing Limits
    Autism in Adults
    Divorce and Mental Health
    Which SSRI Is Best for Panic Disorder?
    CME Post-Test, Adult Autism, TCPR, August 2023
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.